Registry Study on "Control Nocturnal Hypertension to Reach the Target "
ConditionNocturnal Hypertension
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age50-79
SponsorShanghai Institute of Hypertension
About this trial
Ambulatory blood pressure monitoring (ABPM) is a major innovation in the history of hypertension diagnosis. In clinical practice, the most well established indication for using ABPM is to identify patients who have high BP readings in the office but normal readings during usual daily activities outside of this setting or vice versa, and to identify varying 24-h BP profiles. However, in recent years, there has been increasing interest in BP values during sleep, and nocturnal BP is now recognized to be superior to daytime BP in predicting fatal and nonfatal cardiovascular events (stroke, myocardial infarction, and cardiovascular death), especially in medicated patients.
The current direction in the management of hypertension is toward earlier and lower BP control for 24 hours, including the nocturnal and morning periods. Therefore, it may be of great significance to pay attention to the management of nocturnal blood pressure so as to reduce the increased cardiovascular risks.
Information of nocturnal hypertensive patients defined by ABPM was prospectively registered nationwide, and then to investigate whether there was difference in cardiovascular prognosis according to the control of ambulatory nocturnal blood pressure.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age 50-79 years old
Clinical diagnosed hypertension with the use of antihypertensive drugs
Nocturnal hypertension ( nocturnal systolic blood pressure ≥ 130 mmHg and/or nocturnal diastolic blood pressure ≥ 80 mmHg)
A 24-hour ambulatory blood pressure monitoring was performed with validated equipment.
Disqualifiers
Without antihypertensive drug use
Hospitalized hypertension patients
Non-compliant patient
Trial population
primary care clinic, and community sample
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
4,500 Participants
are grouped into 2 trial groupsGroup A: Nocturnal controlled hypertension
Group B: Nocturnal uncontrolled hypertension
Trial outcomes
Primary outcomes
1
The occurrence time of fatal and non-fatal cardiovascular events.
Fatal and non-fatal cardiovascular events, including cardiovascular mortality, non-fatal myocardial infarction, non-fatal stroke, coronary artery bypass grafting or interventional stenting or balloon dilation, and hospitalization for heart failure.
Time frame
From date of enrollment until date of first documented event assessed up to 3 yearsSecondary outcomes
1
The occurrence time of all-cause mortality.
Time frame
From date of enrollment until date of first documented event, assessed up to 3 years2
The occurrence time of fatal and nonfatal stroke.
Time frame
From date of enrollment until date of first documented event assessed up to 3 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov